Active Ingredient History
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, and has been approved in China. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 2)
Adenocarcinoma of Lung (Phase 1)
Angiogenesis Inhibitors (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Bevacizumab (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 2/Phase 3)
Catheters (Phase 2)
Chemoembolization, Therapeutic (Phase 1/Phase 2)
Chemoradiotherapy (Phase 2)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 3)
Death (Phase 2)
Deficiency Diseases (Phase 2/Phase 3)
Dendritic Cells (Phase 2)
Digestive System Neoplasms (Phase 2)
Drug Evaluation (Phase 1/Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Endometrial Neoplasms (Phase 2)
Epstein-Barr Virus Infections (Phase 2)
Esophageal Diseases (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrectomy (Phase 2)
General Surgery (Phase 2)
Glioblastoma (Phase 2)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 3)
Immune Checkpoint Inhibitors (Phase 2)
Immunotherapy (Phase 3)
Immunotherapy, Adoptive (Phase 2)
Killer Cells, Natural (Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Maintenance (Phase 2)
Melanoma (Phase 3)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 3)
Mouth Neoplasms (Phase 2)
Mutation (Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Nasopharyngeal Neoplasms (Phase 3)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasm, Residual (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteosarcoma (Phase 1)
Ovarian Neoplasms (Phase 2)
Oxaliplatin (Phase 2)
Pancreatic Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 2)
Pharmacokinetics (Phase 2)
Precancerous Conditions (Phase 2)
Propranolol (Phase 1)
Radiation Oncology (Phase 2)
Radiosurgery (Phase 2)
Radiotherapy (Phase 2/Phase 3)
Rectal Neoplasms (Phase 2/Phase 3)
Respiratory Tract Diseases (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sepsis (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Therapeutics (Phase 2)
Thoracic Neoplasms (Phase 2)
Thrombosis (Phase 1)
Triple Negative Breast Neoplasms (Phase 4)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue